O Asuphon1, P Montakantikul2, J Houngsaitong2, P Kiratisin3, P Sonthisombat4. 1. Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand. 2. Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand. 3. Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand. 4. Department of Pharmacy Practice, Faculty of Pharmaceutical Sciences, Naresuan University, Phitsanulok, Thailand. Electronic address: paveenasonthi@hotmail.com.
Abstract
OBJECTIVE: The purpose of the study was to determine the optimal dosing regimen of intravenous fosfomycin for the treatment of Pseudomonas aeruginosa (PA) based on PK/PD targets. METHOD: A total of 120 PA isolates were recovered from various clinical specimens at university hospital in Thailand. Minimum Inhibitory Concentrations (MICs) of all the isolates were determined by the E-test method. PK parameters were obtained from a published study. Monte Carlo simulation was performed to calculate the percentage of target attainment (PTA) and cumulative fraction of response (CFR). RESULTS: MIC90 of fosfomycin alone, fosfomycin in combination with carbapenem, carbapenems alone and carbapenems in combination with fosfomycin were >1,024, 1,024, >32 and 32μg/ml, for multidrug resistant (MDR)-PA and 512, 128, 8 and 3μg/ml respectively, for non-MDR PA. Approximately 40% of the non-MDR PA were carbapenem-resistant strains. For non-MDR PA with CRPA, fosfomycin 16g continuous infusion in combination with carbapenems provided %PTA of approximately 80 and %CFR of > 88. While, %PTA and %CFR > 90 were achieved with fosfomycin 24g/day prolonged infusion in combination with carbapenem. CONCLUSIONS: Prolonged infusion of fosfomycin 16 - 24g combined with extended carbapenem infusion could be used in non-MDR PA treatment with CRPA.
OBJECTIVE: The purpose of the study was to determine the optimal dosing regimen of intravenous fosfomycin for the treatment of Pseudomonas aeruginosa (PA) based on PK/PD targets. METHOD: A total of 120 PA isolates were recovered from various clinical specimens at university hospital in Thailand. Minimum Inhibitory Concentrations (MICs) of all the isolates were determined by the E-test method. PK parameters were obtained from a published study. Monte Carlo simulation was performed to calculate the percentage of target attainment (PTA) and cumulative fraction of response (CFR). RESULTS: MIC90 of fosfomycin alone, fosfomycin in combination with carbapenem, carbapenems alone and carbapenems in combination with fosfomycin were >1,024, 1,024, >32 and 32μg/ml, for multidrug resistant (MDR)-PA and 512, 128, 8 and 3μg/ml respectively, for non-MDR PA. Approximately 40% of the non-MDR PA were carbapenem-resistant strains. For non-MDR PA with CRPA, fosfomycin 16g continuous infusion in combination with carbapenems provided %PTA of approximately 80 and %CFR of > 88. While, %PTA and %CFR > 90 were achieved with fosfomycin 24g/day prolonged infusion in combination with carbapenem. CONCLUSIONS: Prolonged infusion of fosfomycin 16 - 24g combined with extended carbapenem infusion could be used in non-MDR PA treatment with CRPA.
Authors: Ester Del Barrio-Tofiño; Carla López-Causapé; Gabriel Cabot; Alba Rivera; Natividad Benito; Concepción Segura; María Milagro Montero; Luisa Sorlí; Fe Tubau; Silvia Gómez-Zorrilla; Nuria Tormo; Raquel Durá-Navarro; Esther Viedma; Elena Resino-Foz; Marta Fernández-Martínez; Claudia González-Rico; Izaskun Alejo-Cancho; Jose Antonio Martínez; Cristina Labayru-Echverria; Carlos Dueñas; Ignacio Ayestarán; Laura Zamorano; Luis Martinez-Martinez; Juan Pablo Horcajada; Antonio Oliver Journal: Antimicrob Agents Chemother Date: 2017-10-24 Impact factor: 5.191
Authors: Krisztina M Papp-Wallace; Elise T Zeiser; Scott A Becka; Steven Park; Brigid M Wilson; Marisa L Winkler; Roshan D'Souza; Indresh Singh; Granger Sutton; Derrick E Fouts; Liang Chen; Barry N Kreiswirth; Evelyn J Ellis-Grosse; George L Drusano; David S Perlin; Robert A Bonomo Journal: J Infect Dis Date: 2019-07-19 Impact factor: 5.226
Authors: D Busse; P Simon; D Petroff; N El-Najjar; L Schmitt; D Bindellini; A Dietrich; M Zeitlinger; W Huisinga; R Michelet; H Wrigge; C Kloft Journal: Antimicrob Agents Chemother Date: 2022-05-23 Impact factor: 5.938
Authors: Natalia V Ortiz Zacarías; Anneke C Dijkmans; Jacobus Burggraaf; Johan W Mouton; Erik B Wilms; Cees van Nieuwkoop; Daan J Touw; Ingrid M C Kamerling; Jasper Stevens Journal: Pharmacol Res Perspect Date: 2018-02
Authors: J Mensa; J Barberán; A Soriano; P Llinares; F Marco; R Cantón; G Bou; J González Del Castillo; E Maseda; J R Azanza; J Pasquau; C García-Vidal; J M Reguera; D Sousa; J Gómez; M Montejo; M Borges; A Torres; F Alvarez-Lerma; M Salavert; R Zaragoza; A Oliver Journal: Rev Esp Quimioter Date: 2018-02-23 Impact factor: 1.553